India’s Supreme Court Directs Patent Office To Review Roche's Valcyte Before Jan. 31
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - India's Supreme Court has directed the Controller General of Patents, Designs and Trade Marks to finalize the patent validity of Roche's Valcyte (valganciclovir) before Jan. 31, 2009. Roche had filed a special leave petition that contested the Madras High Court's earlier decision that directed the Indian patent office to review the product patent granted to Valcyte in 2007
You may also be interested in...
A First In India: Roche Withdraws Patent Claim Over Valganciclovir
Patent lawyers debate whether company’s rationale is a strategic decision.
Indian Patent Office Speeds Up Examination Process; Clears Roche’s Pegasys, Rejects Pfizer’s Caduet and Gilead’s Tamiflu
MUMBAI - Over the last two months, the Indian Patent Office has gone ballistic in clearing patent applications filed by multinational companies for several of their key drugs
Indian Patent Office Speeds Up Examination Process; Clears Roche’s Pegasys, Rejects Pfizer’s Caduet and Gilead’s Tamiflu
MUMBAI - Over the last two months, the Indian Patent Office has gone ballistic in clearing patent applications filed by multinational companies for several of their key drugs